Trial Profile
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adrenocortical carcinoma
- Focus Therapeutic Use
- Acronyms CaboACC
- 12 Jul 2022 Planned End Date changed from 1 Jun 2022 to 30 Apr 2025.
- 12 Jul 2022 Planned primary completion date changed from 1 Dec 2021 to 30 Sep 2024.
- 04 Jun 2019 Trial design for two phase II studies including this study presented at the 55th Annual Meeting of the American Society of Clinical Oncology